Poster

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

Retrieved on: 
torsdag, maj 23, 2024
EC50, Master of Veterinary Science, SARS-CoV-2, Antiviral Research, Science, Virology, COVID19, Conference, Ritonavir, ICAR, Veterinary medicine, Cancer, Drug resistance, Plasma protein binding, Poster, Virus, Pharmaceutical industry

The poster highlights positive results of preclinical experiments using patient isolates of COVID19 virus to define the resistance profile of ratutrelvir, formerly known as travatrelvir or TRX01, Traws’ ritonavir-free Mpro protease inhibitor for COVID19, currently in Phase 1 single and multiple ascending dose (SAD/MAD) escalation studies.

Key Points: 
  • The poster highlights positive results of preclinical experiments using patient isolates of COVID19 virus to define the resistance profile of ratutrelvir, formerly known as travatrelvir or TRX01, Traws’ ritonavir-free Mpro protease inhibitor for COVID19, currently in Phase 1 single and multiple ascending dose (SAD/MAD) escalation studies.
  • “We are very pleased to present the results of resistance studies for ratutrelvir at ICAR2024.
  • We believe the results presented at ICAR provide additional positive data to indicate that ratutrelvir has a differentiated resistance profile compared to nirmatrelvir,” said Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.
  • The poster can be found on the Scientific Presentations section of the Traws Investor Relations web page.

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Uveal melanoma, Patient, Headache, DL2, Carcinoma, Plasma, Acute myeloid leukemia, PD, Thrombocytopenia, Toxicity, ACC, Nausea, Black Majesty, Messenger, Pharmacodynamics, Therapy, Grade 3, Safety, Acute lymphoblastic leukemia, Arm, CDKN1A, MD, Blood, AML, Efficacy, MPN, ALL, Biomarker, ASCO, Șaeș, MDM2, Fatigue, Poster, Society, TPD, Adenoid cystic carcinoma, Aes, Merkel-cell carcinoma, Resource, Vomiting, MCC, DLT, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024, in Chicago, Illinois. Results released in an ASCO abstract today include a data cut-off of January 26, 2024.

Key Points: 
  • Results released in an ASCO abstract today include a data cut-off of January 26, 2024.
  • “We continue to see encouraging data from the trial’s dose escalation phase demonstrating potent upregulation of p53 biomarkers and signs of antitumor activity in patients.
  • The Company expects to complete the study and share additional clinical data to inform the program’s next development steps in 2024 at an upcoming medical meeting.
  • Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and is expected to present data at a medical meeting this year.

IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO

Retrieved on: 
onsdag, maj 22, 2024
Patient, Risk, Food, Pressure ulcer, FDA, Trial of the century, Health, Conference, Food and Drug Administration, Interim, Nursing, Pressure, Poster, HMO, Health care, Quality of life, Infrared, Clalit Health Services, Medical device

Rosh Pina, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform, which addresses significant healthcare needs, today published a poster presentation on its website titled “Near Infra-Red Spectroscopy scanner for early detection of stage 1 pressure injury and deep tissue injury – clinical study results”, which includes data that was presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference in San Antonio, Texas. The poster was also recently shared by Clalit Innovation, which described PressureSafe™ as a “Breakthrough in pressure ulcer diagnosis…” and “Truly groundbreaking impact of an innovative tool!”.

Key Points: 
  • PressureSafe™ is a decision support device that has received U.S. Food and Drug Administration (FDA) listing confirmation for the indication of pressure injuries.
  • IR-MED conducted a usability study in conjunction with two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest HMO in Israel.
  • During the study period, the incidences of pressure injuries were reduced by 50% in comparison to the levels prior to the study.
  • Patient care costs per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries.

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Retrieved on: 
onsdag, maj 22, 2024
ENDO, Abstract, Congenital adrenal hyperplasia, Therapy, SAN, Endocrine system, Poster, Pharmaceutical industry

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts accepted for presentation at the Endocrine Society’s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date.

Key Points: 
  • SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts accepted for presentation at the Endocrine Society’s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date.
  • The abstract for the Phase 2, open-label study of atumelnant* (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission.
  • We plan to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024.
  • The more fulsome data set will be shared within the poster presentations scheduled to be presented on June 3, 2024, at 12:00 – 1:30 pm ET during the Late-Breaking Poster Presentation session.

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

Retrieved on: 
onsdag, maj 22, 2024
Patient, Glioblastoma, Safety, MDNA, Poster, Society, TSX, OTCQB, Annual general meeting, Pharmaceutical industry

TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10 th Annual Oncology Innovation Forum .

Key Points: 
  • TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10 th Annual Oncology Innovation Forum .
  • The forum takes place on Friday, May 31st, 2024, as part of the clinical partnering and investment activities surrounding the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31st-June 4, 2024.
  • Medicenna’s President and CEO, Dr. Fahar Merchant, will lead the Company’s presentation and be available for one-on-one meetings at the Sachs 10th Annual Oncology Innovation Forum as well as during the 2024 ASCO Annual Meeting.
  • Details on the Company’s presentation at the Sachs 10th Annual Oncology Innovation Forum are as follows:
    The Sachs Oncology Innovation Forum brings together thought leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street, to facilitate partnering, funding and investment.

Arbutus to Present Imdusiran Data at EASL Congress 2024

Retrieved on: 
onsdag, maj 22, 2024
HBsAg, Abstract (summary), EASL, Poster, HBV, Congress, CHB, Abstract, Virology, CFBV, Vaccine

The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.

Key Points: 
  • The study remains ongoing and additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data for a subset of study subjects will be presented.
  • Title: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone.
  • Abstracts are available on the EASL Congress 2024 website at https://www.easlcongress.eu/ .
  • The posters are expected to be made available to conference attendees at the start of the meeting on June 5, 2024.

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

Retrieved on: 
onsdag, maj 22, 2024
NUC, EASL, Immune system, Autoimmunity, Disease, Safety, HBV, Congress, Research, PD-1, CHB, Cancer, Hepatitis B virus, Poster, Abstract, Quality of life, Nivolumab, Vaccine

More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.

Key Points: 
  • More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.
  • “We are pleased to present the latest data on our immunotherapeutic candidate, VTP-300, at EASL 2024 updated from the data cut we made in January for the abstracts,” said Bill Enright, CEO of Barinthus Bio.
  • Additional interim data, including NUC discontinuation, Hepatitis B Virus (HBV) markers, immunology and safety data will be presented in the poster.
  • On-treatment, follow-up and NUC discontinuation data including HBV parameters and immunology data will be included in the oral presentation.

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Retrieved on: 
onsdag, maj 22, 2024
Doctor of Philosophy, EASL, Treatment, Genital herpes, Viral, Poster, Safety, SAN, Assembly, Gilead Sciences, HSV, HDV, Cirrhosis, Hepatitis D, Viral hepatitis, Injection, Abstract, Therapy, Biotechnology, Standard of care, Vaccine

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs at upcoming medical congresses. Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024. An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.

Key Points: 
  • Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024.
  • An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.
  • At the International Herpesvirus Workshop, Assembly Bio will present data describing the preclinical profile of ABI-5366, a long-acting helicase-primase inhibitor candidate in development for the treatment of recurrent genital herpes.
  • “We’re excited to present data from both of these potent, long-acting HSV helicase-primase inhibitors at the International Herpesvirus Workshop,” said William Delaney, PhD, chief scientific officer of Assembly Bio.

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Retrieved on: 
onsdag, maj 22, 2024
Food, American Thoracic Society, FDA, SAN, Asthma, Conference, CNTB, Connect, Week, ATS, Poster, Entrepreneurship, FEV1, Pharmaceutical industry

presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.

Key Points: 
  • presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
  • A predefined exploratory analysis showed further improvement in lung function was achieved in patients with eosinophil levels of ≥300 cells/µl.
  • The Company has scheduled an EoP2 meeting with the FDA to discuss rademikibart’s Phase 3 regulatory path in Q2 2024.
  • A copy of the poster presentation will be made available on Connect Biopharma’s website under the “ Our Science ” section.

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

Retrieved on: 
tisdag, maj 21, 2024
Patient, COVID-19, IMV, Food, FDA, Mortality, Tocilizumab, Conference, American Thoracic Society, MD, Hospice and palliative medicine, JAK, Risk, ATS, Intensive care medicine, Poster, Safety, Therapy, Standard of care, Pharmaceutical industry

InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.

Key Points: 
  • InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.
  • Tocilizumab, an anti-IL6R antibody, and baricitinib, a JAK inhibitor, are immunomodulators used in some patients as part of the standard of care treatment in this trial.
  • Day 60 all-cause mortality was 16.4% and 49.3%, respectively (HR 0.25; 95% CI:0.09-0.68, p=0.006), a significant relative reduction.
  • We believe this analysis further supports the life-saving potential of vilobelimab in the acute care setting and indicates our continued commitment to these patients.”